WO2004063150A3 - Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process - Google Patents

Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process Download PDF

Info

Publication number
WO2004063150A3
WO2004063150A3 PCT/US2003/041731 US0341731W WO2004063150A3 WO 2004063150 A3 WO2004063150 A3 WO 2004063150A3 US 0341731 W US0341731 W US 0341731W WO 2004063150 A3 WO2004063150 A3 WO 2004063150A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
phenyl
same
alkynyl
Prior art date
Application number
PCT/US2003/041731
Other languages
French (fr)
Other versions
WO2004063150A2 (en
Inventor
David R Elmaleh
Sangwoon Choi
Alan J Fishman
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Priority to AU2003300147A priority Critical patent/AU2003300147A1/en
Publication of WO2004063150A2 publication Critical patent/WO2004063150A2/en
Publication of WO2004063150A3 publication Critical patent/WO2004063150A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Piperidine or piperazine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compounds are characterized by the formulae: (I), (II), (III), (IV), (V) wherein: n is an integer of 1 to 6; X, Y, Z1 and Z2 can be the same or different and are hydrogen, halo, haloalkyl, alkyl, aryl, (C1-C6)alkoxy, N-alkyl, (C2-C6)acyloxy, N-alkylene, -SH, -SR, wherein R is from the same group as R1 and R2 and can be the same or different than R1 and R2, amino, nitro, cyano, hydroxy, C(=O)OR6, -C(=O)NR5R4, NR3R2, or S(=O)kR1 wherein k is 1 0r 2, and R1 to R6 are independently hydrogen or (C1-C6)alkyl; R1 and R2 can be the same or different and are hydrogen, (C1-C6)alkyl, hydroxyalkyl or mercaptoalkyl, -C(=O)OR1, cyano, (C1-C6)alkenyl, (C2-C6) alkynyl, or 1, 2, 4-oxadiazol-5-yl optionally substituted at the 3-position by Z4 wherein any (C1-C6)alky, (C1-C6)alkanoyl, (C2-C6)alkenyl or (C2-C6)alkynyl can optionally be substituted by 1, 2 or 3 Z; R7 can be hydrogen, O or phenyl; R8 can be hydrogen, phenyl, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl; Z4 is (C1-C6)alkyl or phenyl, optionally substituted by 1, 2 or 3 Z1; W is O or S; T is amino or C1-C6aminoalkyl; A is N or C; T is C1-C6alkyl or sulfonyl and V is alkyl (C0-C6), alkenyl, alkynyl, haloaryl, alkyl phenol, alkyl halophenyl, and R1 or R2 as indicated above and D is phenyl, naphrhyl, thienyl or pyridinyl.
PCT/US2003/041731 2003-01-06 2003-12-31 Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process WO2004063150A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003300147A AU2003300147A1 (en) 2003-01-06 2003-12-31 Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43788503P 2003-01-06 2003-01-06
US60/437,885 2003-01-06

Publications (2)

Publication Number Publication Date
WO2004063150A2 WO2004063150A2 (en) 2004-07-29
WO2004063150A3 true WO2004063150A3 (en) 2005-06-02

Family

ID=32713245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041731 WO2004063150A2 (en) 2003-01-06 2003-12-31 Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process

Country Status (2)

Country Link
AU (1) AU2003300147A1 (en)
WO (1) WO2004063150A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101819472B1 (en) * 2017-02-14 2018-01-17 전남대학교산학협력단 Novel 1,4-substituted piperazine or piperidine compounds and pharmaceutical composition comprising the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476129A (en) * 1982-06-29 1984-10-09 Gist-Brocades N.V. 4-[2-[Bis(halophenyl)methoxy]-ethyl]-α-(substituted phenyl)-1-piperazinealkanol derivatives, processes for their preparation and pharmaceutical preparations containing them
US5652240A (en) * 1992-07-31 1997-07-29 Pharmacia Aktiebolag Pyridyl-and pyrimidylpiperazine derivatives
US6387389B1 (en) * 1996-10-31 2002-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476129A (en) * 1982-06-29 1984-10-09 Gist-Brocades N.V. 4-[2-[Bis(halophenyl)methoxy]-ethyl]-α-(substituted phenyl)-1-piperazinealkanol derivatives, processes for their preparation and pharmaceutical preparations containing them
US5652240A (en) * 1992-07-31 1997-07-29 Pharmacia Aktiebolag Pyridyl-and pyrimidylpiperazine derivatives
US6387389B1 (en) * 1996-10-31 2002-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use

Also Published As

Publication number Publication date
AU2003300147A8 (en) 2004-08-10
WO2004063150A2 (en) 2004-07-29
AU2003300147A1 (en) 2004-08-10

Similar Documents

Publication Publication Date Title
JO2613B1 (en) Organic Compounds
MX2009004900A (en) Thiazole and oxazole-substituted arylamides.
MX2008016423A (en) Tetrazole-substituted arylamides.
BR122012009489B8 (en) process for producing 2-ethoxy-1-{[2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazol- (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 7-carboxylate or a salt thereof, pharmaceutical composition, and use
NO20085169L (en) Crystalline solvates and complexes of (1S) -1,5-anhydro-L-C- (3 - ((phenyl) methyl) phenyl) -D-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes
DE602007004851D1 (en) A2A ADENOSINE RECEPTOR ANTAGONISTS
IL183876A0 (en) Aminocarboxylic acid derivative and medicinal use thereof
ATE515505T1 (en) HETEROCYCLIC FXR BINDING COMPOUNDS
NO20055688L (en) Organic compounds
NO20060324L (en) [1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2006023881A3 (en) T type calcium channel blockers and the treatment of diseases
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
WO2005030120A3 (en) Antiangiogenic agents
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
EP1817311A4 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
MY147404A (en) Process for preparation of n-benzoyl-staurosporine
WO2007025897A3 (en) Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
WO2006003013A3 (en) NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17β-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1
HUP0303034A2 (en) Novel 7-azaindole-derivatives, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
NO20062202L (en) Amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3,4-dihydro-2H-chromene-6-yl derivatives, processes and intermediates for their preparation, and drugs containing these compounds
WO2004067482A3 (en) Substituted anilide ligands for the thyroid receptor
WO2004066929A3 (en) Cycloalkyl containing anilide ligands for the thyroid receptor
NO20074346L (en) New heterocyclic oxime compounds, processes for their preparation and pharmaceutical compositions containing them
GB0428416D0 (en) Organic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP